Ingrid Glimelius

Affiliated to research

About me

I am a medical oncologist working with mainly lymphoma- and testicular cancer patients at Uppsala University Hospital. Since year 2002 I perform lymphoma research and since 2011 I have been collaborating with Karin Ekström Smedby and been affiliated to the Cancer Epidemiology group at the Division of Clinical Epidemiology, Karolinska Institutet. In addition to my clinical work I perform clinical phase I-III studies and epidemiological studies. I supervise PHD-students and I teach both medical students and senior physicians. I have been awarded Senior Clinical Investigator Cancer Award from the Swedish Cancer Society in spring 2019.

Research description

My primary research interest is in malignant lymphomas, with a specific focus on Hodgkin lymphoma and Mantle cell lymphoma. In addition, I have an interest in Ovarian and Testicular cancer.

Mantle cell lymphoma (MCL) is one of the lymphoma subtype that with combination chemotherapy still has a poor survival, although prognostic heterogeneity exists. Using epidemiological “real-world data” I investigate treatment selection and the prognostic implication of associated diseases. I am also national principal investigator for the ENRICH-trial: A randomized phase III study for elderly MCL patients with randomization between Rituximab-Ibrutinib AND Rituximab-chemotherapy (Bendamustine or CHOP) with the aim to test if a chemotherapy free concept can improve survival. I am also local PI for the VALERIA trial in Uppsala testing Lenalidomide-Venetoclax and Rituximab for relapsed/refractory mantle cell lymphoma patients.

In addition, my research interests are in young cancer patients, with a specific focus on survivorship, particularly childbearing potential and long-term prognosis for Hodgkin lymphoma patients. I describe late adverse effects from both chemotherapy and radiotherapy. Recently we have in collaboration with other researcher and specifically Caroline Weibull ( published a series of publications regarding childbearing potential in Hodgkin lymphoma survivors (please see below).

I also study other lymphatic malignancies, testicular cancer and ovarian cancer both regarding aetiology, prognosis and late-effects from treatment.

Teaching portfolio

Teacher Medical School, Oncology, Uppsala University since year 2010

Teacher research school in Epidemiology, Karolinska Institutet 2013-2014

Steering committee National Research School in Oncology, NATION, since 2017

Examiner for project-works in Medical School, Uppsala University since 2017


MD, Uppsala University 2001

PHD, Uppsala University 2009, Hodgkin lymphoma – an interplay between tumour cell and microenvironment 

MD, specialist Internal Medicine 2011

MD, specialist Oncology 2013

Associate Professor in Oncology 2016

Good Clinical Practice, Investigator Site Personnel ICH-GCP 2017

Senior consultant, Oncology 2019

Loading bibliometrics...